Prelude Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Prelude Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-147	Closed	-$1K	–	2197
2019 Q4	$1K	Sell	147 -15	-9%	-$47	﹤0.01%	1863
2019 Q3	$1K	Buy	+162	New	+$585	﹤0.01%	1652
2017 Q4	–	Sell	-15,900	Closed	-$63K	–	1820
2017 Q3	$63K	Buy	15,900 +7,900	+99%	+$36.3K	0.01%	1030
2017 Q2	$41K	Sell	8,000 -26,900	-77%	-$151K	﹤0.01%	1063
2017 Q1	$241K	Buy	34,900 +23,500	+206%	+$184K	0.02%	506
2016 Q4	$107K	Buy	11,400 +5,600	+97%	+$50.4K	0.01%	804
2016 Q3	$57K	Buy	5,800 +800	+16%	+$10.8K	0.01%	1005
2016 Q2	$71K	Sell	5,000 -2,047	-29%	-$31.9K	0.01%	879
2016 Q1	$99K	Buy	7,047 +3,151	+81%	+$46.2K	0.01%	768
2015 Q4	$79K	Buy	+3,896	New	+$60.1K	0.01%	904
2015 Q3	–	Sell	-215	Closed	-$3K	–	1884
2015 Q2	$3K	Buy	+215	New	+$4.12K	﹤0.01%	1636

Other funds holding AGTC

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Prelude Capital Management's AGTC Position: Q1 2020 in Review

Prelude Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q1 2020, closing a stake of 147 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in AGTC in Q2 2015 and held it in 11 quarters. The position peaked at $241K in Q1 2017. 59 funds tracked by Wall St. Rank hold AGTC as of Q1 2020.

Prelude Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 147 Applied Genetic Technologies Corporation shares in Q1 2020, an estimated $1K.
Prelude Capital Management first reported a position in Applied Genetic Technologies Corporation in Q2 2015 and held it in 11 quarters.
Prelude Capital Management's Applied Genetic Technologies Corporation position peaked at $241K in Q1 2017.
59 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.